Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature

References

• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11
   PubMedGoogle Scholar
• Porter JB. Practical management of iron overload. Br J Haematol 2001;115(2):239-52
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program 2011;2011:451-8
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996;95(1):26-36
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Farmaki K, Carson S, et al. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 2012;3:119-29
   PubMedGoogle Scholar
• Berdoukas V, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol 2011;4(1):17-26
   PubMed Web of Science ®Google Scholar
• Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984;58(2):369-73
   PubMed Web of Science ®Google Scholar
• Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999;55(1):1-6
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455-62
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10(1):12
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355(9220):2051-2
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-93
   PubMed Web of Science ®Google Scholar
• Fernandes JL, Fabron A Jr, Verissimo M. Early cardiac iron overload in children with transfusion-dependent anemias. Haematologica 2009;94(12):1776-7
   PubMedGoogle Scholar
• Yang G, Liu R, Peng P, et al. How early can myocardial iron overload occur in Beta thalassemia major? PLoS One 2014;9(1):e85379
   PubMed Web of Science ®Google Scholar
• Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103(5):1934-6
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22(23):2171-9
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006;8(3):543-7
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009;120(20):1961-8
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88(5):489-96
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107(9):3738-44
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107(9):3733-7
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115(14):1876-84
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Chouliaras G, Moraitis P, et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009;11:20
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42
   PubMed Web of Science ®Google Scholar
• Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91(9):1187-92
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Udelson JE, Arai AE, et al. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013;128(3):281-308
   PubMed Web of Science ®Google Scholar
• PubMed. Bethesda, MD: US National Library of Medicine: national Institutes of Health. Available from: www.ncbi.nlm.nih.gov/pubmed/ [Last accessed 24 March 2014]
   Google Scholar
• Web of science. New York: Thompson Reuters. Available from: http://thomsonreuters.com/thomson-reuters-web-of-science/ [Last accessed 24 March 2014]
   Google Scholar
• Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25(4):329-42
   PubMed Web of Science ®Google Scholar
• Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008;24(6):1609-21
   PubMed Web of Science ®Google Scholar
• Karnon J, Tolley K, Vieira J, Chandiwana D. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. Clin Drug Investig 2012;32(12):805-15
   PubMed Web of Science ®Google Scholar
• Kim J, Kim Y. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea. Value Health 2009;12(Suppl 3):S78-81
   Google Scholar
• Keshtkaran A, Javanbakht M, Salavati S, et al. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Transfusion 2013;53(8):1722-9
   PubMed Web of Science ®Google Scholar
• Ladis V, Chouliaras G, Berdoukas V, et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol 2010;85(4):335-44
   PubMed Web of Science ®Google Scholar
• Ho WL, Chung KP, Yang SS, et al. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. J Formos Med Assoc 2013;112(4):221-9
   PubMedGoogle Scholar
• McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess 2009;13(1):iii-v. ix-xi, 1-121
   PubMedGoogle Scholar
• Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig 2011;31(7):493-505
   PubMed Web of Science ®Google Scholar
• Ketchum ES, Dickstein K, Kjekshus J, et al. The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction. Eur Heart J Acute Cardiovasc Care 2014;3(1):46-55
   PubMedGoogle Scholar
• Bentley A, Gillard S, Spino M, et al. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective. Pharmacoeconomics 2013;31(9):807-22
   PubMedGoogle Scholar
• Farmaki K, Angelopoulos N, Agnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with β-thalassaemia major. Br J Haematol 2006;134(4):438-44
   PubMed Web of Science ®Google Scholar